

SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME DEXAMETHASONE ACETATE, USP (Anhydrous)(Micronized)

PRODUCT CODE 1905

SUPPLIER MEDISCA Inc.

Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063

MEDISCA Pharmaceutique Inc.

Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8

21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2

MEDISCA Australia PTY LTD

Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047

Unit 7, Heritage Business Park

5-9 Ricketty Street, Mascot, NSW 2020

EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300

NSW Poisons Information Centre: 131 126

National Chemical Emergency Centre 44(0)1235239670

RECOMMENDED USES Manufacturing and Compounding

RESTRICTIONS ON USE Not applicable

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION Toxic to Reproduction (Category 2)

Specific Target Organ Toxicity - Repeated Exposure (Category 1) - (endocrine system)

PICTOGRAM

Not applicable

SIGNAL WORD Danger
HAZARD STATEMENT(S) Harmful if sw

Harmful if swallowed or inhaled

Suspected of damaging fertility or the unborn child.

Causes damage to organs (endocrine system) through prolonged or repeated exposure.

Suspected of causing cancer.

ADVERSE PHYSIOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL

EFFECTS

Last Revision: 02/2023

PRECAUTIONARY STATEMENT(S)

Prevention Obtain, read and follow all special instructions before use.

Do not handle until all safety precautions have been read and understood.

Do not breathe dust/fume/gas/mist/ vapors/spray. Do not eat, drink or smoke when using this product.

Wash thoroughly after handling.

Wear protective gloves, protective clothing, eye and face protection and hearing protection.



G

Response IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical

advice/attention. Wash contaminated clothing before reuse.

IF EXPOSED: Get emergency medical help immediately. Call a poison center or doctor.

Storage Store locked up.

Disposal Dispose of contents and/or container in accordance with local regulations.

HMIS CLASSIFICATION Health Hazard 2 Flammability 0

Reactivity 0 Personal Protection

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

CHEMICAL NAME
9-fluoro-11β, 17, 21-trihydroxy-16α-methylpregna-1, 4-diene-3, 20-dione 21-acetate

BOTANICAL NAME Not applicable

SYNONYM Dexamethasone 21-acetate

CHEMICAL FORMULA

C24H31FO6

CHEMICAL FAMILY

COrticosteroid

CAS NUMBER

1177-87-3

ALTERNATE CAS NUMBER

Not applicable

MOLECULAR WEIGHT 434.51

IOLECULAR WEIGHT

CHEMICAL NAME	CAS NUMBER	EC NUMBER	% BY WEIGHT
DEXAMETHASONE ACETATE	1177-87-3	214-646-8	100
(Anhydrous)			

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

SECTION 4: FIRST-AID MEASURES

IN CASE OF EYE CONTACT Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek

medical aid.

IN CASE OF SKIN CONTACT Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Call a

physician.

MEDICAL ATTENTION AND SPECIAL

TREATMENT

COMPOSITION

Get emergency medical help.

SYMPTOMS CAUSED BY EXPOSURE Not expected to present a significant hazard under anticipated conditions of normal use.

SECTION 5: FIREFIGHTING MEASURES

SPECIFIC HAZARDS ARISING FROM

THE CHEMICAL

Not applicable

FLAMMABLE PROPERTIES

Last Revision: 02/2023

May be combustible at high temperature



HAZARDOUS COMBUSTION PRODUCTS

SUITABLE & UNSUITABLE EXTINGUISHING MEDIA

PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS

Under fire conditions, hazardous fumes will be present.

Small fire: dry chemical, CO₂ or water spray. **Large fire:** dry chemical, CO₂, alcohol resistant foam or water spray. Do not get water inside containers.

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

SECTION 6: ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate

ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

METHODS & MATERIAL FOR

CONTAINMENT
CLEANUP PROCEDURE

Last Revision: 02/2023

On land, sweep or shovel into suitable containers. Minimize generation of dust.

Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean

the affected area. Do not flush into sewerage system or to drains.

REFERENCE TO OTHER SECTIONSSee Section 7 for information on safe handling. See Section 8 for information on personal protection equipment.

See Section 13 for disposal information.

SECTION 7: HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash

thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use

appropriate containment to avoid environmental contamination.

CONDITIONS FOR SAFE STORAGE

Store in original container, tightly sealed container, protected from direct sunlight, in a dry, and well-ventilated area, away from incompatible materials. Store in accordance with local regulations. Eliminate all ignition

sources. Separate from oxidizing materials. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid

environmental contamination.

STORAGE CONDITIONS Store in original container, tightly sealed, protected from direct sunlight and moisture.

Store at 25, excursions permitted between 15° and 30°.

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

Chemical Name: DEXAMETHASONE ACETATE (Anhydrous) CAS #: 1177-87-3

	Country	Limit value-8 hours		Limit value-Short Term		IDLH	REL	Advisory	Notes
		ppm	mg/m³	ppm	mg/m³				
OSHA	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
ACGIH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
NIOSH	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
WEEL	USA	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A



HSIS	Australia	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
HSE	UK	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A
GESTIS	Add Country	N/L	N/L	N/L	N/L	N/L	N/L	N/A	N/A

N/L = Not listed; N/A = Not Available

PELs are 8-hour TWAs = Limit value - Eight hours

Ceiling or Short-Term TWA = STEL = Limit value - Short term

EXPOSURE GUIDELINES Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable

fraction: 5 mg/m3

PERSONAL PROTECTIVE EQUIPMENT Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's

> eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to minimize contact with skin. Respirators: Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Thermal Hazards: For products representing a

thermal hazard, appropriate Personal Protective Equipment should be used.

SPECIFIC ENGINEERING CONTROLS Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

BIOLOGICAL MONITORING Not available **CONTROL BANDING** Not available

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

Last Revision: 02/2023

DESCRIPTION Clear, white to off-white, odorless powder.

SOLUBILITY Practically insoluble in water: freely soluble in methanol, in acetone, and in dioxane

SOLUBILITY	Practically insoluble in water; freely soluble in methanol, in acetone, and in dioxane.										
ODOR	Odorless										
FLAMMABILITY	May be combustible at high temperature										
AUTO-IGNITION TEMPERATURE	Not available	BOILING POINT	Not available	DECOMPOSITION TEMPERATURE	Not available						
EVAPORATION RATE	Not available	EXPLOSIVE LIMIT	Not available	FLASH POINT	Not available						
log P (OCTANOL-WATER)	2.91	LOWER FLAMMABLE/ EXPLOSIVE LIMIT(S)	Not available	MELTING/FREEZING POINT	(238 - 240)°C, (460.4-464)°F						
PARTICLE CHARACTERISTICS	Not available	OXIDIZING PROPERTY	Not available	рН	Not available						
RELATIVE DENSITY (WATER = 1)	Not available	SPECIFIC GRAVITY	Not available	UPPER FLAMMABLE/ EXPLOSIVE LIMIT(S)	Not available						
VAPOR DENSITY (AIR = 1)	Not available	VAPOR PRESSURE	< 0.0000001 kPa (25°C)	VISCOSITY	Not available						

The physical data presented above are typical values and should not be construed as a specification.



SECTION 10: STABILITY AND REACTIVITY

REACTIVITY Not established

CHEMICAL STABILITY Stable under recommended storage conditions

INCOMPATIBLE MATERIALS Strong oxidants

HAZARDOUS DECOMPOSITION

Toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and other gases may occur

PRODUCTS

HAZARDOUS POLYMERIZATION Will not occur

POSSIBLITY OF HAZARDOUS

REACTION

CONDITIONS TO AVOID

/ill not occur

Not established

Moisture, sunlight and extreme temperatures

SECTION 11: TOXICOLOGICAL INFORMATION

ACUTE TOXICITY Oral: Rat: LD50: (mg/kg): Not available

Dermal: Rabbit LD50: (mg/kg): Not available Inhalation: Rat: LC50: (mg/L/4hr): Not available

Due to lack of data the classification is not possible.

SKIN CORROSION/IRRITATIONDue to lack of data the classification is not possible.

SERIOUS EYE DAMAGE/EYE

IRRITATION

INFORMATION

Last Revision: 02/2023

RESPIRATORY SENSITIZATIONDue to lack of data the classification is not possible.

SKIN SENSITIZATION Based on available data, the classification criteria are not met.

Suspected skin sensitiser: The Toolbox profiler Protein binding alerts for skin sensitization by OASIS v1.3

gives an alert for skin sensitisation.

GERM CELL MUTAGENICITY

Based on available data, the classification criteria are not met.

Suspected mutagen: The Toolbox profiler Protein binding alerts for Chromosomal aberration by OASIS v1.1

gives an alert for mutagenicity.

CARCINOGENICITY OSHA DEXAMETHASONE ACETATE is not listed.

NTP DEXAMETHASONE ACETATE is not listed.

IARC DEXAMETHASONE ACETATE is not evaluated.

California This product does not contain any chemicals known to the State of California to cause

Proposition 65 cancer, birth defects, or any other reproductive harm.

ADDITIONAL CARCINOGENICITY Based on available data, the classification criteria are not met.

Suspected carcinogen: The Toolbox profiler Carcinogenicity (genotox and nongenotox) alerts by ISS gives an

alert for carcinogenicity.

REPRODUCTIVE TOXICITY Suspected of damaging fertility or the unborn child.

Most studies have concluded that therapeutic use of corticosteroids by pregnant women does not cause adverse effects on the fetus. A small increase in the incidence of cleft palate was seen in some human studies. Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be observed for signs of hypoadrenalism. Epidemiological studies have not shown an association between therapeutic use of the base during pregnancy and an increased incidence of birth defects. Reproductivity studies in animals

administered the base have shown maternal and fetal toxicity and teratogenicity.

Suspected toxic for reproduction: The Toolbox profiler DART scheme v.1.0 gives an alert for toxicity to

reproduction.



SPECIFIC TARGET ORGAN TOXICITY -

SINGLE EXPOSURE

SPECIFIC TARGET ORGAN TOXICITY -

REPEATED EXPOSURE

ASPIRATION HAZARDS

SIGNS AND SYMPTOMS OF

EXPOSURE

Based on available data, the classification criteria are not met.

Causes damage to organs (endocrine system) through prolonged or repeated exposure.

Based on available data, the classification criteria are not met.

ROUTES OF EXPOSURE:

Oral, Dermal, Inhalation, Eye contact

EARLY ONSET SYMPTOMS RELATED TO EXPOSURE:

Not available

DELAYED HEALTH EFFECT FROM EXPOSURE:

Corticosteroids: Fluid and electrolyte imbalance. Cushing's syndrome. Adrenal suppression. Immune system

depression. Withdrawal

Symptoms related to the physical, chemical, and toxicological characteristics:

Glucocorticoid effects: Bone fractures. Back pain. Joint pain or stiffness. Weakness. Increased appetite. Infection. Delayed wound healing. Thinning skin. Bruising. Purple lines on skin. Increased hair growth. Acne. Redistribution of body fat. Menstrual irregularities. Impotence. Headache. Increased sweating. Eye pain.

Change in vision. Mental or behavioral changes. Mineralocorticoid effects: Swelling. Confusion.

Light-headedness. Nausea. Vomiting. Numbness. Tremors. Withdrawal effects: Fever. Muscle pain. Joint pain.

Malaise.

Cross sensitivity:

Persons sensitive to other corticosteroids may also be sensitive to this material.

Medical conditions aggravated by exposure:

History of malaria. Tuberculosis. Myasthenia gravis. Corticosteroids: Heart disease. High blood pressure. Diabetes. Epilepsy. Glaucoma. Hypothyroidism. Osteoporosis. Peptic ulcer. Systemic fungal infection. Mental

disorders. Impaired liver or kidney function.

POTENTIAL HEALTH EFFECTS Inhalation Harmful if inhaled. May cause upper respiratory tract irritation.

Ingestion Harmful if swallowed.

Skin May be harmful if absorbed through skin. May cause skin irritation. May cause allergic

reaction.

Eyes May cause eye irritation.

SECTION 12: ECOLOGICAL INFORMATION

ECOTOXICITY EC50: 48 Hr: Crustacea: (mg/L): Not available

LC50: 96 Hr: Fish: (mg/L): Not available

EC50: 72 or 96 Hr: Algae (or other aqua plants): (mg/L): Not available

PERSISTENCE AND DEGRADABILITY Suspected persistent in the environment: The Danish QSAR database contains information indicating that the

substance is predicted as non readily biodegradable.

BIOACCUMULATIVE POTENTIAL LogPow: 2.91

MOBILITY IN SOIL Water Solubility: 5.47 mg/L (25°C)

Henry's Law Constant: 7.73E-12 atm-m³/mole (25°C)

OTHER ADVERSE EFFECTS Not available

Last Revision: 02/2023

This product is not intended to be released into the environment

SECTION 13: DISPOSAL CONSIDERATIONS



DISPOSAL METHODS

Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

SECTION 14: TRANSPORT INFORMATION

UN PROPER SHIPPING NAME Not dangerous good

UN NUMBER Not applicable
CLASS Not applicable

AUSTRALIA

PACKING GROUP

HAZCHEM Not Applicable

ΕU

TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE

IBC CODE

Not listed

Not applicable

ENVIRONMENTAL HAZARDS Not available SPECIAL SHIPPING INFORMATION Not applicable

SECTION 15: REGULATORY INFORMATION

UNITED STATES REGULATIONS

Chemical Name & CAS	CERCLA 40 CFR Part 302.4	SARA (Title III) 40 CFR Part 372.65	EPA 40 CFR Part 355		Right-to-know Pennsylvania New Jersey Massachusetts			California Prop 65
DEXAMETHASONE ACETATE 1177-87-3	N/L	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

AUSTRALIAN REGULATIONS

Chemical Name & CAS	Poisons and Therapeutic Goods	Therapeutic Goods Act	Code of Practices - Illicit Drug Precursors	Poisons Standard	Work Health and Safety Regulations	Inventory of Industrial Chemcials
DEXAMETHASONE ACETATE	N/L	Listed as Schedule	N/L	Listed*	N/L	N/L
1177-87-3		4*				

N/L = Not Listed

EU REGULATIONS

Chemical Name & CAS	REACH ANNEX XVII	REACH ANNEX XIV	EC 1005/2009	EC 850/2004	EC 1107/2009	PIC - Prior Informed Consent Regulation	EC 2012/18
DEXAMETHASONE ACETATE 1177-87-3	N/L	N/L	N/L	N/L	N/L	N/L	N/L

N/L = Not Listed; X = Listed

Last Revision: 02/2023

Any EU regulation not listed above is not applicable to this product.



SUBJECT TO INTERNATIONAL AGREEMENT

Not applicable

NOTES *Listed as the base

SECTION 16: OTHER INFORMATION

REFERENCES

ABBREVIATIONS AND ACRONYMS

Available upon request

ACGIH - American Conference of Governmental Industrial Hygienists; AIHA WEEL – American Industrial Hygiene Association Workplace Environment Exposure Levels; CAESAR – Computer Assisted Evaluation of industrial chemical Substances According to Regulations; CAS – Chemical Abstract Service; CERCLA – Comprehensive Environmental Response, Compensation, and Liability Act; EC50 – Effective Concentration, 50%; EPA – Environmental Protection Agency; GHS – Global Harmonized System; HMIS – Hazardous Materials Information System; HSE – Health and Safety Executive; HSIS – Hazardous Substances Information System; IARC – International Agency for Research on Cancer; IDLH - Immediately Dangerous to Life or Health; IRFMN – Ready Biodegradability Model; ISS – Instituto Superiore Sanità; LC50 – Lethal Concentration, 50%; LD50 – Lethal Dose, 50%; MSHA - Mine Safety and Health Administration; NIOSH – National Institute for Occupational Safety and Health; NTP – National Toxicology Program; OSHA PEL – Occupational Safety & Health Administration Permissible Exposure Limits; QSAR – Quantitative Structure-activity relationship; REL - Recommended Exposure Limit; SARA – Superfund Amendments and Reauthorization Act; STEL – Short Term Exposure Limit; TLV – Threshold Limit Value; TWA – Time Weighted Average; WHMIS – Workplace Hazardous Materials Information System

SUPERSEDES

02/2023 05/2021

For a list of changes to the SDS since the last version, please communicate with MEDISCA at

www.medisca.com

DISCLAIMER

LAST REVISION

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

SUPPLEMENTARY INFORMATION

Last Revision: 02/2023

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.